Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/09
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 02/28/07
End: 10/31/13
Due: 10/31/14
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy | NCT01144195 | Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials | user2@example.com | None | 2009-09-30 | - | - | - | - | 2025-07-14 |
| XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | NCT00557713 | Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials | user2@example.com | None | 2007-02-28 | 2013-10-31 | 2014-10-31 | - | - | 2025-07-14 |